@article{edb63e714681480d9436ec0f4bc9b05a,
title = "Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management",
abstract = "The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and S{\'e}zary syndrome (SS). One of the most common adverse events seen with mogamulizumab in MF/SS patients is rash. Because of the protean nature of MF/SS and the variable clinical and histopathological features of mogamulizumab-associated rash, healthcare providers may have difficulty distinguishing rash from disease, and may not be aware of appropriate treatment strategies for this generally manageable adverse event. The objective of this report was to combine results from published literature with experiences and recommendations from multiple investigators and institutions into clinical best practice recommendations to assist healthcare providers in identifying and managing mogamulizumab-associated rash. Optimal management, which includes biopsy confirmation and steroid treatment, requires a multidisciplinary approach among oncology, dermatology, and pathology practitioners. Infographic: [Figure not available: see fulltext.].",
keywords = "Cutaneous T-cell lymphoma, Eruption, Mogamulizumab, Mycosis fungoides, Rash, S{\'e}zary syndrome",
author = "Musiek, {Amy C.M.} and Rieger, {Kerri E.} and Martine Bagot and Choi, {Jennifer N.} and Fisher, {David C.} and Joan Guitart and Haun, {Paul L.} and Horwitz, {Steven M.} and Huen, {Auris Onn Lay} and Kwong, {Bernice Y.} and Lacouture, {Mario E.} and Noor, {Sarah J.} and Rook, {Alain H.} and Lucia Seminario-Vidal and Vermeer, {Maarten H.} and Kim, {Youn H.}",
note = "Funding Information: The development of this report and the Journal{\textquoteright}s Rapid Service fee were funded by Kyowa Kirin, Inc. Drs. Horwitz, Lacouture, and Noor are supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748. Funding Information: Amy Musiek reports serving on an advisory board for Kyowa Kirin during the conduct of the study and serving on an advisory board for Helsinn and Kyowa Kirin, as well as serving as an investigator for Pfizer, Menlo, Elorac, Soligenix, miRagen, and Connect outside the submitted work. Kerri Rieger reports personal fees from, and serving on an advisory board for, Kyowa Kirin during the conduct of the study. Martine Bagot reports personal fees from, and serving on an advisory board for, Kyowa Kirin during the conduct of the study and personal fees from, and serving on an advisory board for, Takeda, Innate Pharma, and Helsinn-Recordati outside the submitted work. Jennifer Choi reports serving on an advisory board for Kyowa Kirin outside the submitted work. David Fisher reports serving on an advisory board for Kyowa Kirin during the conduct of the study and outside the submitted work. Joan Guitart reports honoraria from Kyowa Kirin during the conduct of the study and grants from Soligenix, Galderma, and Elorac for serving as an investigator on clinical trials outside the submitted work. Paul Haun reports serving on an advisory board for Kyowa Kirin during the conduct of the study. Steven Horwitz reports grants and personal fees from Kyowa Kirin during the conduct of the study and grants and personal fees from Corvus, ADC Therapeutics, Affimed, Aileron, Celgene, Forty Seven Inc., Kyowa Kirin, Takeda, Portola, Seattle Genetics, and Trillium, Verastem, grants from Daiichi Sankyo, and personal fees from Acrotech Biopharma, Astex, BeiGene, miRagen, Merck, Innate Pharma, Bristol Myers Squibb, Mundipharma, C4 Therapeutics, Janssen, Kura Oncology, Myeloid Therapeutics, ONO Pharmaceuticals, and Vividion outside the submitted work. Auris Huen reports personal fees from, and serving on an advisory board for, Kyowa Kirin outside the submitted work. Bernice Kwong reports personal fees from, and serving on an advisory board for, Kyowa Kirin during the conduct of the study and personal fees from, and serving as a consultant for, Oncoderm outside the submitted work. Mario Lacouture reports personal fees from, and serving on an advisory board for, Kyowa Kirin during the conduct of the study and grants and personal fees from Berg, Lutris, Paxman, Novocure, Johnson & Johnson, US Biotest, AstraZeneca, Novocure, QED, Janssen, Novartis, Hoffmann-La Roche, EMD Serono, Genentech, Seattle Genetics, Lutris, OnQuality, Azitra, NCODA, and Apricity outside the submitted work. He is funded in part through NIH/NIAMS grant U01 AR077511 and NIH/NCI Cancer Center Support Grant P30 CA008748. Sarah Noor reports personal fees from, and serving on an advisory board for, Kyowa Kirin during the conduct of the study. Alain Rook has nothing to disclose. Lucia Seminario-Vidal reports grants and personal fees from Kyowa Kirin and Novartis, grants from Soligenix, Eisai, Innate Pharma, Eli Lilly, Amgen, Boehringer Ingelheim, Celgene, AbbVie, Bristol Myers Squibb, Pfizer, and Glenmark, and personal fees from Helsinn, and Aptis Partners outside the submitted work. Maarten Vermeer reports grants from Kyowa Kirin during the conduct of the study and grants from, and serving on an advisory board for, Kyowa Kirin and grants from Takeda outside the submitted work. Youn Kim reports grants and personal fees from, and serving on an advisory board for, Kyowa Kirin during the conduct of the study. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2022",
month = jan,
doi = "10.1007/s13555-021-00624-7",
language = "English (US)",
volume = "12",
pages = "29--40",
journal = "Dermatology and Therapy",
issn = "2193-8210",
publisher = "Springer Verlag",
number = "1",
}